Sex Differences in Reported Adverse Drug Reactions to Angiotensin-Converting Enzyme Inhibitors

Sex differences in adverse drug reactions (ADRs) associated with angiotensin-converting enzymeinhibitors (ACEIs) remain poorly understood owing to a lack of sex-specific ADR data from clinicaltrials. 1 Postmarketing pharmacovigilance data, containing structured and detailed ADR information,may play an important role in such analyses. However, these data are often not corrected forprescription numbers and therefore cannot separate sex differences in ADR risk from sex differencesin prescription rates. To investigate whether women report more ACEI-related ADRs than men aftercorrection for sex-specific prescription and describe sex differences in reported ADR types, wecombined data from the global pharmacovigilance database VigiBase and the prescription-correctedDutch pharmacovigilance database Lareb.